Market News / Story
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
ACCESS Newswire ·
ACCESS Newswire reports: KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update. Lexaria's DehydraTECH™ technology is currently being evaluated both by Lexaria and pharmaceutical industry partners for use within the rapidly growing GLP-1 receptor agonist and weight-loss/diabetes drug industries. Those industry segments were valued at $62.8 billion in 2025 and…